5th Annual Summit to Feature New Stem Cell Therapies

WAYNE, Pa., Jan. 8 /PRNewswire/ -- Six new stem cell therapies, all forecast to reach physicians in 2010, will be featured at the 5th Annual Stem Cell Summit on February 16 in New York City. These new therapies include allograft products, innovative forms of autologous stem cell technologies, and at least one FDA-approved stem cell drug. New studies showing rehydration of the disc nucleus, regeneration of new heart muscle and others are also on the agenda.

The Stem Cell Summit is an annual gathering of stem cell and biomaterial company executives, scientists and investors to explore the therapeutic applications of stem cells, the successful path to stem cell product commercialization, and the latest investment opportunities within the space. The Summit features 35 corporate presentations, a scientific panel, separate tracks for stem cell tools & instruments, and a closing reception. It is an intensive one-day event held at Bridgewaters in New York City's historic South Street Seaport.

                  The presenting stem cell companies include:

    Aastrom Biosciences, Inc.     INCELL Corporation, LLC
    AllCells, LLC                 International Stem Cell Corp.
    AlloSource                    Lonza Group Ltd.
    Aldagen, Inc.                 MaxCyte, Inc.
    ArunA Biomedical, Inc.        Mesoblast Limited
    Athersys, Inc.                Novocell, Inc.
    BioE Inc.                     Osiris Therapeutics, Inc.
    Cardiogenesis Corp.           Pluristem Therapeutics Inc.
    Cellerix, S.A.                ProChon Biotech, Ltd.
    Celtigen Therapeutics, LLC    Progenitor Cell Therapy, Inc.
    Core Dynamics Ltd.            SpineSmith Partners LP
    Cytori Therapeutics, Inc.     Stematix, Inc.
    Gamida Cell Ltd.              Stemina Biomarker Discovery, Inc.
    Garnet BioTherapeutics, Inc.  TiGenix NV
    Genzyme Biosurgery            Tissue Genesis, Inc.
    Glycosan BioSystems, Inc.     TxCell SA
    Harvest Technologies Corp.    Vet-Stem, Inc.
    Histogen, Inc.

In addition to the company and scientific presentations, Robin R. Young, CFA, a leading medical technologies analyst, will deliver his updated 10-year market forecast for the industry. "In 2009, the number of new market entrants was notable, but there were some difficulties with regard to clinical trials. Nevertheless, sales of stem cell therapies continue to grow extremely rapidly in the United States. We now estimate that revenues from stem cell therapies will surpass $2.5 billion by 2015 and that the industry will support a $10 billion valuation," said Young.

                 5th Annual Stem Cell Summit Facts at a Glance

    When:            Tuesday, February 16, 2010

    Where:           Bridgewaters
                     11 Fulton Street
                     New York City

    Admission:       $1,200 advance registration by January 31, 2010
                     $1,500 (February 1 - 16, 2010)

    Information:     A detailed agenda and online registration are
                     available at www.stemcellsummit.com.

    Contact:          Lisa Carpenter
                      RRY Publications, LLC
                      877-817-6450
                      [email protected]

SOURCE Stem Cell Summit